Biotech Losers: Spark Therapeutics, Inc. (NASDAQ:ONCE), Regulus Therapeutics Inc. (NASDAQ:RGLS), Ohr Pharmaceutical, Inc. (NASDAQ:OHRP), Osiris Therapeutics, Inc. (NASDAQ:OSIR), Ophthotech Corporation (NASDAQ:OPHT)

Spark Therapeutics Inc. (NASDAQ:ONCE) on Wednesday reported a loss of $14.3 million in its second quarter. On a per-share basis, the Philadelphia-based company said it had a loss of 60 cents. Spark Therapeutics, Inc. (NASDAQ:ONCE) belongs to Healthcare sector. Its weekly performance is -5.46%. On last trading day company shares ended up $57.50. Spark Therapeutics, Inc. (NASDAQ:ONCE) distance from 50-day simple moving average (SMA50) is -12.35%.

Regulus Therapeutics Inc. (NASDAQ:RGLS) reported a net loss of $21.0 million and $35.5 million for the three and six months ended June 30, 2015, compared to a net loss of $12.0 million and $24.7 million for the same periods in 2014. Basic and diluted net loss per share was $0.41 for the three months ended June 30, 2015, compared to basic and diluted net loss per share of $0.28 and $0.29, respectively, for the same period in 2014. Regulus Therapeutics Inc. (NASDAQ:RGLS) shares fell -6.69% in last trading session and ended the day at $7.25. RGLS return on assets is -42.20%. Regulus Therapeutics Inc. (NASDAQ:RGLS) quarterly performance is -44.23%.

Ohr Pharmaceutical, Inc. (NASDAQ:OHRP), announced that it will report financial results for the third quarter ended June 30, 2015 after the market close on Thursday, August 6 2015. The Company will also hold a live investor conference call and webcast at 5:00pm Eastern.On 05 August, Ohr Pharmaceutical, Inc. (NASDAQ:OHRP) shares fell -7.84% and was closed at $2.82. OHRP EPS growth in last 5 year was -32.60%. Ohr Pharmaceutical, Inc. (NASDAQ:OHRP) year to date (YTD) performance is -66.19%.

Osiris Therapeutics, Inc. (NASDAQ:OSIR) reported Product revenues during the second quarter of 2015 were $23.7 million, compared to $13.3 million during the second quarter of 2014, an increase of 78%. Gross margin during the second quarter remained the same as the second quarter of 2014 at 78%. Gross profit was $18.5 million during the second quarter of 2015 and $10.4 million during the same period of 2014. Osiris Therapeutics, Inc. (NASDAQ:OSIR) ended the last trading day at $18.83. Company weekly volatility is calculated as 5.64% and price to cash ratio as 13.72. Osiris Therapeutics, Inc. (NASDAQ:OSIR) showed a weekly performance of -9.90%.

Ophthotech Corporation (NASDAQ:OPHT) reported a net loss for the quarter ended June 30, 2015 of $37.1 million, or ($1.08) per diluted share, compared to a net loss of $73.0 million, or ($2.19) per diluted share for the same period in 2014. For the six months ended June 30, 2015, the Company reported a net loss of $30.5 million, or ($0.89) per diluted share, compared to a net loss of $93.7 million, or ($2.85) per diluted share, for the same period in 2014. Ophthotech Corporation (NASDAQ:OPHT) shares fell -6.98% in last trading session and ended the day at $64.76. OPHT return on assets is -18.40%. Ophthotech Corporation (NASDAQ:OPHT) quarterly performance is 41.89%.

Leave a Reply

Your email address will not be published. Required fields are marked *